

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



An Overview on Cryptococcal Meningitis

Marcia S. C. Melhem and Mara Cristina S. M. Pappalardo
*Adolfo Lutz Institute, Laboratory Reference Center and Emilio Ribas,
 Research Institute of the Secretary of Health of São Paulo State,
 Brazil*

1. Introduction

Cryptococcosis is a systemic disease caused by the yeast *Cryptococcus* spp. *Cryptococcus neoformans* and *C. gattii* are the etiological agents of fungal meningoencephalitis. Chronic meningitis is the most common clinical presentation of cryptococcosis. In contrast with the acute meningitis, patients with chronic meningitis develop an indolent course of symptoms for at least four weeks like headache, nausea, decreased memory and comprehension. Cerebral cryptococcomas can also cause significant neurological morbidity, and these mass lesions require relief of increased intracranial pressure and prolonged antifungal therapy. Although cryptococcosis is considered one opportunistic infection of the central nervous system and lungs, extra neural and non-pulmonary forms may be found. The disease is almost always associated with impaired immunity, and occurs in patients with lymph proliferative disorders, steroid therapy and organ transplantation. Before the acquired immune deficiency syndrome (AIDS) the cases with cryptococcosis were sporadic. Despite of the highly active antiretroviral therapy-HAART, acute mortality due to HIV-associated cryptococcal meningitis remains unacceptably high (Lortholary et al., 2006), and consequently, this disease remains a leading cause of death in Africa, Asia, and Brazil (French et al., 2002; Vidal et al., 2008; Pappalardo et al., 2009).

Cryptococcosis has been documented in few (~3%) of solid-organ transplant recipients with 68% of the cases occurring one year after transplantation, and almost half cases have pulmonary cryptococcal infection. The disease is limited to the lungs only in 6% to 33% of cases, although cryptococcal meningitis and disseminated infections have been documented in up to 60% of patients (Husain et al., 2001; Vilchez et al., 2002; Singh et al., 2007; Shaariah et al., 1992). Data on non-transplant patients or presumably immunocompetent hosts presenting cryptococcal meningitis are scarce, because the majority of patients prior to the HIV epidemic were significantly immunosuppressed, receiving steroids or having cancer or other degenerative diseases (Perfect et al., 2010).

2. Cryptococcosis and AIDS

Cryptococcus neoformans is yeast with a tropism for the central nervous system, and 70-90% of infections caused by this species manifested as meningitis, after spores inhalation and hematologic dissemination. Meningitis is frequently associated to the pulmonary form. In immunosuppressed patients with pulmonary cryptococcosis, meningitis should be always

ruled out by lumbar puncture (Mitchell & Perfect, 1995). Cryptococcal meningitis is a common and often fatal opportunistic infection in HIV-infected patients, especially in developing countries and in patients with CD4 cells $< 100/\mu\text{L}$. Incidence of cryptococcosis decreased in the era HAART, but the incidence and mortality of the disease are still high in some areas of the world. Recent review suggests that there are ~1 million new cases and at least 500.000 annual deaths world-wide due to HIV-associated cryptococcosis (Park et al., 2009).

Computed tomography or magnetic resonance imaging head scans should be done in all patients prior to any diagnostic or therapeutic lumbar puncture, with focal neurological signs or impaired mental functions. Patients with HIV disease generally do not have hydrocephalus or cryptococcal mass lesions and these exams commonly are normal or show cerebral atrophy without obstruction or other abnormality (Graybill et al., 2000).

The most common signs and symptoms are headaches, fever, nausea, vomiting, lethargy, coma, memory loss over 2 to 4 weeks; however, sometimes patients only refer general bodily discomfort. Patients can also present with pulmonary or cutaneous manifestations with or without apparent neurologic disease (Perfect et al., 2010).

The diagnosis of the meningeal cryptococcosis through mycological procedures is easy and based on the visualization of encapsulated yeast cells in the cerebral spinal fluid specimen, and immunological assays. If cryptococcal meningitis is confirmed, extra neural sites should be discharged by means of screening of cutaneous lesions, procedures for blood cultures, examination of urine, pleural fluid, sputum, prostatic fluid, and others clinical specimens for detect the etiological agent..

Antifungal drugs more commonly used for treat cryptococcal meningitis are amphotericin B deoxycholate, amphotericin B lipid complex or liposomal formulation, flucytosine, and fluconazole (Perfect et al., 2010). Ideally, antifungal therapy should rapidly sterilize the central nervous system and this should be the primary focus of any induction strategy (Bicanic et al., 2007). The antifungal therapy in cryptococcal meningitis in AIDS patients is divided into 3 phases: induction (for at least 2 weeks), consolidation (for a minimum of eight weeks) and maintenance or suppression phase.

The induction phase aims the achievement of sterilization of cerebral spinal fluid, or reduction of fungal burden. The consolidation phase warrants maintenance of negative cultures and normalization of clinical parameters. Some experts and guidelines suggest a routine lumbar puncture at the second week, with prolongation of the induction phase if the cerebrospinal fluid culture is not yet sterile. The drug of choice for induction is amphotericin B (0,7-1,0 mg/kg per day intravenously), and fluconazole is the choice for consolidation [400 mg (6 mg/kg) per day orally]. Fluconazole should be introduced for consolidation regimen whenever the mental status recovered, fever, headache and meningeal symptoms disappear, and/or yeast culture results are negative at the second week. Despite the theoretic antagonism between amphotericin B and fluconazole, most animal model data suggests that both drugs together are a very effective combination against *C. neoformans* (Menichetti et al., 1996; Larsen et al., 2004; Larsen et al., 2005; Pappas et al., 2009; Perfect et al., 2010).

Maintenance therapy should be initiated after completion of primary therapy with an induction and consolidation regimen, and continued until there is evidence of persistent

immune reconstitution with successful HAART. Since a cure doesn't exist in AIDS patients, maintenance should be done for at least one year with 200 mg/daily of fluconazole (standard for consolidation and maintenance), with CD4 cell count > 100 cells/ μ L and undetectable or very low HIV RNA level sustained for ≥ 3 months (minimum of 12 months of antifungal therapy). Itraconazole is an alternative, albeit less effective, choice for maintenance therapy. Oral itraconazole if patient is intolerant of fluconazole, may be administered (200 mg per day or a higher dosage 200 mg twice per day orally) (Denning et al, 1989).

The management of cryptococcosis is difficult, particularly in some developing countries where flucytosine is no more commercialized and liposomal or lipid complex amphotericin B formulations are not affordable. The nephrotoxicity of amphotericin B deoxycholate represents a big challenge for the physicians in such regions (Sharkey et al., 1996). Furthermore the treatment of increased intracranial pressure represents another serious issue since approximately one-half of HIV-infected patients have elevated baseline opening intracranial pressures requiring drainage of cerebral spinal fluid daily (Bicanic et al., 2009). Medications other than antifungal drugs are not useful in the management of increased intracranial pressure in cryptococcal meningoencephalitis (Perfect et al. 2010).

The rapid clearance of infection by sterilization of cerebrospinal fluid associated with clinical improvement on day 14 of treatment is predictive of a good evaluation in the 10th week (Robinson et al., 1999). The rate of clearance of cryptococcal colony-forming units is a clinically meaningful endpoint. Maybe deaths within two weeks are nearly all related to cryptococcal infection, whereas, after this time, deaths are increasingly related to other complications of late-stage HIV infections or extended hospitalization (Bicanic et al., 2009). The good control of elevated CSF pressure and symptoms are very important, and they are some of the most critical determinants in the outcome of cryptococcal meningitis (Perfect et al., 2010). This elevated CSF pressure level is generally linked to a high burden of yeast in the cerebrospinal fluid (Bicanic et al., 2009). Factors that indicate a bad outcome in cryptococcal meningitis include abnormal mental status, poor host inflammatory response (cerebrospinal fluid white cells <20/mL), raised CSF opening pressure (> 25 cm H₂O), high organism burden, extra neural sites and the lack of effective antifungal treatment. Some studies confirm the greater fungicidal activity of amphotericin B plus flucytosine to improve prognosis (Brouwer et al., 2004).

Potential complications in management of cryptococcal infection, includes increased intracranial pressure, immune reconstitution inflammatory syndrome, drug resistance, and cryptococcomas. Opportunistic infections such bacteremia, toxoplasmosis, histoplasmosis, or oropharyngeal candidosis, tumors, drug-related complications may occur in heavily immunocompromised patients. Moreover, the long-time of hospitalization, never less than two weeks, increased the risk for hospital infections. Development of classic hydrocephalus later during treatment and follow-up can occur. Furthermore, impaired vision, mental deficit and cranial nerve palsies are described sequels of cryptococcosis.

After discontinuation of maintenance therapy, relapses with positive culture result may occur and so careful follow-up of patients is necessary. Patients will need follow-up lumbar punctures and intracranial pressure should be measured. Reinstitution of fluconazole maintenance therapy should be considered if the CD4 cell count decreases to <100 cells/mL and/or the serum cryptococcal antigen titer increases [Zolopa et al., 2009]

2.1 Cryptococcosis and IRIS

Immune reconstitution inflammatory syndrome (IRIS) consists of clinical manifestations compatible with enormous tissue inflammation in patients with rapid improvement in cellular immunity and worsening in central nervous system signs and/ or symptoms of the disease. About 30% of patients with cryptococcal meningitis will develop IRIS when HAART is initiated (Bicanic et al., 2006; Antinori et al., 2009). Perfect et al. (2010) suggest a wide range of two to ten weeks after initiation of cryptococcosis therapy to introduce HAART. The exact moment to start HAART in patients with cryptococcal meningitis to avoid immune reconstitution inflammatory syndrome, is still uncertain.

3. Etiologic agents

Cryptococcus neoformans and *Cryptococcus gattii* cause nearly all human and animal cryptococcal infections. In addition to these common species, there are nearby 15 other members of this genus which have appeared as human clinical isolates, such as *C. laurentii*, *C. luteolus* (80% of non-*neoformans* and non-*gattii* cases), *C. albidus*, *C. diffluens*, and *C. uniguttulatus* (Heitman et al. 2011). *Cryptococcus gattii* can be discerned from *C. neoformans* using a wide range of microbiological and molecular techniques. A simple and classical method is the use of canavanine-glycine-bromothymol blue (CGB) medium, which allows *C. gattii* but not *C. neoformans* to grow changing the color medium from green-yellowish to blue. Molecular approaches yield determine distinct genotypes among the species. Polymerase chain reaction (PCR) fingerprinting, restriction fragment length polymorphism (RFLP), analysis of specific loci, and amplified fragment length polymorphism (AFLP) fingerprint analysis, and multi-locus sequence typing scheme (Meyer et al., 2009) are molecular tools (Meyer et al., 2009). Furthermore, interspecies hybrid forms have been isolated from clinical samples, and they seem to present a higher virulence potential than regular *C. gattii* or *C. neoformans* isolates (Boekhout et al., 2001).

The species differs in many aspects and improved surveillance should enable better assessment of the local incidence of these two species and also clinical manifestation and course associated to each species. Whereas *C. neoformans* primarily affects persons infected with human immunodeficiency virus worldwide, *C. gattii* primarily affects HIV-uninfected persons in tropical and subtropical regions (Pappalardo and Melhem, 2003; Chaturvedi et al, 2005; Martins et al., 2007; Heitman et al. 2011).

It noteworthy the emergence of *C. gattii* in temperate climate regions that suggests the pathogen might have adapted to a new climatic niche or that climatic warming might have created an environment for spore survival and propagation of this species. *Cryptococcus gattii* is more likely to cause cryptococcomas, and seems to be less responsive to antifungal drugs (Gomez-Lopes et al., 2008).

The profile of antifungal susceptibility can be assessed through *in vitro* antifungal susceptibility testing. Performance of these tests may help not only to monitor the development of resistance in *Cryptococcus* isolates, but could also determine the best antifungal therapy, predicting possible failures due to a resistant strain. Antifungal susceptibility testing is indeed a recognized useful tool to aid the treatment of *Candida* infections. References broth microdilution methods for this genus are described in document M27-A3 of the Clinical and Laboratory Standards Institute – CLSI, and in the doc.

E.Def 7.1 of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (CLSI, 2008, Subcommittee on Antifungal Susceptibility Testing of the ESCMID, 2008). Although the reference methodologies of CLSI and EUCAST are different, the results are very similar and results are comparable.

Determination of resistance in isolates of *Cryptococcus*, quite distinct yeast in which fermentation is absent, the micro dilution methods present some technical problems. The most relevant one is the low growth of *Cryptococcus* strains due to the oxygen limited environment found in the microdilution plates. So, the standard methods developed for *Candida* are not still completely reliable for test *Cryptococcus* isolates and efforts have been made toward standardization of antifungal susceptibility testing of *Cryptococcus* and other non-fermentative yeasts (Zaragoza et al., 2011).

The minimum inhibition concentration (MIC) of antifungal drugs against clinical and environmental *Cryptococcus* strains has been extensively studied. *Cryptococcus neoformans* has been more frequently assessed for its *in vitro* susceptibility to a wide variety of antifungal compounds, including the new triazoles posaconazole, voriconazole, ravuconazole, and isavuconazole. Otherwise, few studies using relatively small sets of *C. gattii* isolates have been performed to investigate their *in vitro* susceptibilities to these drugs. Since fluconazole may last for a very long period of time, development of resistance to this agent has been reported both *in vivo* and *in vitro*. Many studies pointed out a significant emergence of clinical isolates of *C. neoformans* which present high fluconazole-MICs (MIC >4 mg/L) in different geographical regions (Aller et al., 2000; Dias et al., 2006; Pfaller et al., 2004). Resistance to fluconazole or to other azole compounds is not a cause of concern in the continent of America, where 3% to 10% of strains present high MIC. On opposite, the data from African, Cambodian and Spanish *C. neoformans* isolates showed high fluconazole-MICs (Bicanic et al., 2006; Perkins et al., 2005; Pfaller et al., 2004; Sar et al., 2004). It should be also pointed out that some authors did not find any correlation with clinical failure and the *in vitro* MIC data (Dannaoui et al., 2006). Therefore, the interpretation of the data is quite difficult since there are not interpretative clinical breakpoints for distinguish between resistant or susceptible *Cryptococcus* isolates that could predict failure or clinical success. However, breakpoints have not been defined yet, it is worth performing antifungal susceptibility testing against sequential isolates obtained from patients under antifungal therapy. An increased in MICs values during the monitoring could predict development of resistance of the original strain resulting in therapeutic concerning. Moreover, heteroresistance to fluconazole in *C. neoformans* or *C. gattii* is a phenomenon that could play a role in clinical failure (Mondon et al., 1999; Varma, and Kwon-Chung, 2010).

The identification of amphotericin B resistant organisms seems to be more difficult however, as reference methods fail to detect it and trustworthy comparisons have not been done. Consistent detection of AMB resistance *in vitro* in *Cryptococcus neoformans* has proven difficult, and few studies demonstrated that majority of the initial isolates are susceptible to the polyene (Lozano-Chiu et al., 1998; Rodero et al., 2000a). Time-kill curves, a methodology to measure the fungicidal activity of amphotericin B, have been evaluated to identify resistance or tolerance to this antifungal agent in *Cryptococcus* isolates (Rodero et al., 2000b). Yeast isolates with amphotericin B MICs 2 mg/L are extremely uncommon, and therefore any strain with a MIC > 2 mg/L should be considered as potentially resistant to this polyene (CLSI, 2008).

4. Laboratory identification of *Cryptococcus* in a routine clinical laboratory

The distinguishing feature of *Cryptococcus* genus is a polysaccharide capsule, and techniques that detect this cryptococcal structure and its components are the most useful tools as diagnostic tests. Evaluation of spinal fluid is essential in diagnosing central nervous system disease. The yeast cells of *Cryptococcus* are spherical in shape and approximately 5 to 7 μm in diameter while the capsules vary enormously in their thickness and are of a few micrometers of average. A rapid, simple and inexpensive procedure employs India ink staining to detect the encapsulated cells of *Cryptococcus* in pellets from centrifuged cerebrospinal fluid and other specimens. The lower limit of detection of India ink is $\sim 10^3$ to 10^4 yeast cell/ml. Disadvantages include the poor sensitivity of the technique in diagnosing cryptococcal meningitis in non-HIV-infected patients (30 to 72%) compared with culture. The sensitivity of India ink is high ($\sim 80\%$) for patients with overwhelming infection such as HIV-infected patients (Kwon-Chung and Bennett, 1992; Heitman et al. 2011).

False-positive results can occur if inexperienced readers interpret lymphocytes or fat droplets as fungal cells. The capsular polysaccharide antigen that can be detected using commercial systems and represents the most valuable rapid test for the laboratory diagnosis of cryptococcosis. During infection, the capsular antigen is solubilized in cerebrospinal fluid, serum, urine and fluid recovered from the lungs. Almost all high fungal burden patients will have a positive serum and cerebrospinal fluid. Commercial kits typically demonstrate 90 to 100% sensitivity and 97 to 100% specificity for cerebrospinal fluid compared with culture and clinical diagnosis. However, in patients without AIDS the sensitivity of serum cryptococcal antigen in diagnosing cryptococcal meningitis is $\sim 60\%$. The level of detection of most kits is at least 10 ng of antigen/ml. The most common testing format to detect antigen is latex agglutination assay. Moreover, antigen detection can be quantitative as the greatest dilution of the fluid that gives a positive result. Uncommon false-positive results can be encountered, particularly in serum contaminated with synovial fluid, in presence of rheumatoid factor. In addition, false-positive results can occur in patients with collagen vascular disease, chronic meningitis, malignancy ($<0.3\%$), or even presenting a yeast infection caused by *Trichosporon*. Many kits include an enzymatic or heat pre-treatment in order to minimize the false-positive results, and incorporate a control reagent. In cases in which physicians doubt a positive result, they may ask the laboratory personnel to treat the specimen with 2, β -mercaptoethanol, as it eliminates non-specific reactions. False-negative results were described in low organism burden infections and for capsule-deficient *Cryptococcus*. The latex assay also yields false-negative reactions due to a prozone effect that can be improved by specimen serial dilutions. An enzyme immunoassay is also available to detect glucuronoxylomannan, the principal polysaccharide component. The enzymatic assay is slightly more sensitive than latex assay; similar to latex test, false-positive and false-negative results can occur (Kwon-Chung et al, 1981).

Measuring capsular antigen titers in serial clinical specimens for monitoring cerebrospinal fluid or serum cryptococcal antigen levels is useful in the management of cryptococcosis in non-AIDS patients. Decrease in antigen titers has limited value in the management of meningitis in such cases. Although it is expected that the titers should change after a few weeks of therapy, there is no evidence that titers predict or correlate with clinical and mycological outcomes (Kwon-Chung and Bennett, 1992).

The commercial (1,3) β -D-glucan assay detects a polysaccharide component of the cell wall of several pathogenic fungi, but given the limited experience to date with this test in cryptococcosis cases, there is no recommendation of using this test in the diagnosis of cryptococcosis.

Histological stains for tissue sections for reveal *Cryptococcus* cells includes Gomori methenamine silver and calcofluor white, that are broad-spectrum fungal histochemical stains for fungi regardless of type. The best histological procedure uses mucicarmine, alcian blue, and periodic acid-Schiff that stain the capsule and Fontana-Masson stain, which interacts with the cell wall.

Culture techniques will remain the mainstay of the diagnosis of this infection. Culturing for *Cryptococcus* may be appropriate, even when the CSF profile is unremarkable. Blood, CSF, urine, and other clinical specimens should be cultured for fungi. Yeasts cells growth in 2 to 7 days in classical Sabouraud dextrose agar, typically as brilliant, mucous, pale colored colonies. Besides de capsular cell, one of the defining characteristics of *Cryptococcus neoformans* and *C. gattii* is its ability to synthesize a dark cell wall-associated pigment (melanin) when grow in media containing phenolic compounds, such Birdseed agar. Identification based on conventional biochemical and physiological assays, which are routinely used in a clinical laboratory for yeasts, can be difficult or even impossible for conclusive identification of *Cryptococcus* species. Laboratories should recognize that *C. gattii* cannot be differentiated from *C. neoformans* by conventional laboratory methods. *C. gattii* can only be differentiated from *C. neoformans* by specific biochemical or molecular testing. Laboratories should seek for definitive identification at an appropriate reference laboratory.

5. Conclusion

In conclusion, cryptococcosis remains a challenging management issue around the world and all patients presenting symptomatic increased intracranial pressure should be tested for HIC-infection, and screened for cryptococcal meningitis for receive early antifungal therapy. Relapses of symptoms and signs can occur during or after treatment and patients should be monitored for IRIS, drug resistance or compliance issues.


6. References

- Aller AI, Martin-Mazuelos E, Lozano F; et al.. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. *Antimicrob Agents Chemother.* 2000; 44(6) : 1544-1548
- Antinori S, Ridolfo A, Fasan M et al. AIDS-associated cryptococcosis:a comparison of epidemiology,clinical features and outcome in the pre-and-post-HAART eras. Experience of a single centre in Italy. *HIV Med* 2009;10:6-11
- Bicanic T, Harrison TS, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. *Clin Infect Dis* 2006; 43: 1069-1073.
- Bicanic T,Meintjes G, Wood R et al. Fungal burden,early fungicidal activity,and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients with amphotericin B or fluconazole.*Clin Infect Dis* 2007 ;45 :76-80
- Bicanic T, Brouwer AE, Meintjes G et al. Relationship of cerebrospinal fluid pressure,fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. *AIDS* 2009; 23:701-706

- Bicanic T, Muzoor C, Brouwer AE, Meintjes G, Longley N et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. *Clin Infect Dis* 2009; 49:702-9
- Byrnes, E. J., III, W. Li, Y. Lewit, H. Ma, K. Voelz, P. Ren, D. A. Carter, V. Chaturvedi, R. J. Bildfell, R. C. May, and J. Heitman. Emergence and pathogenicity of highly virulent *Cryptococcus gattii* genotypes in the northwest United States. *PLoS Pathog.* 2010; 6:e1000850.
- Boekhout, T., B. Theelen, M. Diaz, J. W. Fell, W. C. Hop, E. C. Abeln, F. Dromer, and W. Meyer. Hybrid genotypes in the pathogenic yeast *Cryptococcus neoformans*. *Microbiol.* 2001; 147:891-907.
- Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. *Lancet* 2004; 363:1764-7
- Chaturvedi, S., M. Dyavaiah, R. A. Larsen, and V. Chaturvedi. *Cryptococcus gattii* in AIDS patients, southern California. *Emerg. Infect. Dis.* 2005; 11:1686 -1692.
- Chuck MN, Sande MA. Infections with *Cryptococcus neoformans* in the acquired immunodeficiency syndrome. *N Eng J Med* 1989;321:794-799
- Clinical and Laboratory Standards Institute. Reference Method for broth dilution antifungal susceptibility testing of yeast, Approved standard. Third Edition. M27-A3 2008; 28:1-25.
- Dannaoui E, Abdul M, Arpin M, et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. *Antimicrob Agents Chemother* 2006;50: 2464-2470
- Denning DW, Tucker RM, Hanson LH, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. *Arch Intern Med* 1989; 149: 2301-2308.
- Dias ALT, Matsumoto F, Melhem MSC, Silva GS, Auler ME, Siqueira AM, Paula CR. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends on antifungal drug susceptibility testing of Brazilian *Cryptococcus neoformans* Isolates. *J Med Microbiol* 2006; 55: 1693- 1699
- French N, Gray K, Watrea C et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. *AIDS* 2002;16:1031-8
- Graybill JR, Sobel J, Saag M et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. *Clin Infect Dis* 2000;30: 47-54
- Gomez-Lopez A, Zaragoza O, Anjos Martins MA, Melhem MC, Rodriguez-Tudela JL, Cuenca-Estrella M. *In vitro* susceptibility of *Cryptococcus gattii* clinical isolates. *Clin Microbiol Infect* 2008; 14: 727-730
- Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, and Casadevall A. *Cryptococcus*: From Human Pathogen to Model Yeast. Washington, D.C., ASM Press, 2011. 620pp
- Husain S, Wagener MM, Singh N. *Cryptococcus neoformans* infection in organ transplant recipients: variables influencing clinical characteristics and outcome. *Emerg Infect Dis* 2001; 7:375-381.
- Kwon-Chung KJ, Bennett JE. *Medical Mycology*. Philadelphia, Lea & Febiger, 1992. 866p
- Kwon-Chung KJ, Hill WB, Bennett J. New, special stain for histopathological diagnosis of Cryptococcosis. *J. Clin. Microbio.* 1981; 13: 383-387
- Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. *Antimicrob Agents Chemother* 2004;48:985-91

- Larsen RA, Bauer M, Thomas AM et al. Correspondence of *in vitro* and *in vivo* fluconazole dose-response curves for *Cryptococcus neoformans*. *Antimicrob Agents Chemother* 2005; 49: 3297-301
- Lortholary O, Poizat G, Zeller V et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. *AIDS* 2006; 20: 1764-7
- Lozano-Chiu M, Paetznick VL; Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among *Cryptococcus neoformans* clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. *J Clin Microbiol*. 1998; 36: 2817-2822
- Martins MA, Pappalardo MCSM, Melhem MSC, Pereira-Chiocola VL. Molecular diversity of serial *Cryptococcus neoformans* isolates from AIDS patients in the city of São Paulo, Brazil. *Mem Inst Oswaldo Cruz* 2007; 102: 777-783.
- Menichetti F, Fiorio M, Tosti A et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. *Clin Infect Dis* 1996; 22: 838-40
- Meyer, W., A. Castaneda, S. Jackson, M. Huynh, E. Castaneda, and the IberoAmerican Cryptococcal Study Group. Molecular typing of IberoAmerican *Cryptococcus neoformans* isolates. *Emerg. Infect. Dis.* 2003; 9: 189 -195.
- Meyer, W., D. M. Aanensen, T. Boekhout, M. Cogliati, M. R. Diaz, M. C. Esposto, M. Fisher, F. Gilgado, F. Hagen, S. Kaocharoen, A. P. Litvintseva, T. G. Mitchell, S. P. Simwami, L. Trilles, M. A. Viviani, and J. Kwon-Chung. Consensus multi-locus sequence typing scheme for *Cryptococcus neoformans* and *Cryptococcus gattii*. *Med. Mycol.* 2009; 47: 561-570.
- Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of *Cryptococcus neoformans*. *Clin Microbiol Rev* 1995; 8: 515-548
- Mondon P, Petter R, Amalfitano G et al. Heteroresistance to fluconazole and voriconazole in *Cryptococcus neoformans*. *Antimicrob Agents Chemother.* 1999; 43: 1856-1861
- National Committee for Clinical Laboratory Standards (NCCLS) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - 3rd ed., M27-A3. Wayne, PA: NCCLS.
- Pappalardo MCSM, Melhem MSC. Cryptococcosis: a review of the Brazilian experience for the disease. *Rev Inst Med Trop Sao Paulo* 2003; 45: 299-305
- Pappalardo MCSM, Szesz MW, Martins MA, Baceti LB, Bonfietti LX et al. Susceptibility of clinical isolates of *Cryptococcus neoformans* to amphotericin B using time-kill methodology. *Diag Microbiol and Infect Dis* 2009; 64: 146-151
- Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. *Clin Infect Dis* 2009; 48: 1175-83
- Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG et al. Estimation of the global burden of cryptococcal meningitis among people living with HIV/AIDS. *AIDS* 2009; 23: 525-30
- Perfect JR, Casadevall A. Cryptococcosis. *Infect Dis Clin N Am* 2002; 16: 837-874
- Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2010; 50: 291-322
- Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of *Cryptococcus neoformans* var. *neoformans*. *J Antimicrobial Chemother* 2005; 56: 1144-1147.
- Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, et al. *In vitro* activities of voriconazole, posaconazole and fluconazole against 4,169 clinical isolates of *Candida* spp and

- Cryptococcus neoformans* collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. *Diag Microbiol Infect Dis* 2004; 48: 201-205.
- Robinson PA, Bauer M, Leal ME et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. *Clin Infect Dis* 1999;28:82-92
- Rodero L, Cordoba S, Cahn P, Hochenfellner F, Davel G, Canteros C, et al. *In vitro* susceptibility studies of *Cryptococcus neoformans* isolated from patients with no clinical response to amphotericin B therapy. *J Antimicrobiol Chemother* 2000-a; 45: 239- 242.
- Rodero L, Córdoba S, Cahn P, Soria M, Lucarini M, Davel G, et al. Timed-kill curves for *Cryptococcus neoformans* isolated from patients with AIDS. *Med Mycology* 2000-b;38: 201-207
- Rodriguez-Tudela JL, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Denning D et al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. *Clin. Microbiol. Infect.* 2007; 9(8), 1-7
- Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M et al. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. *Clin. Microbiol. Infect.* 2008; 14(4), 398-405
- Sar B, Monchy D, Vann M, Keo C, Sarthou JL, et al. Increasing in vitro resistance to fluconazole of *Cryptococcus neoformans* Cambodian isolates: April 2000 to March 2002. *J Antimicrob Chemother* 2004; 54: 563-565
- Shaariah W, Morad Z, Suleiman AB. Cryptococcosis in renal transplant recipients. *Transplant Proc* 1992; 24:1898-1899.
- Singh N, Alexander BD, Lortholary O, et al. *Cryptococcus neoformans* in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. *J Infect Dis* 2007; 195:756-764. 72.
- Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. *Clin Microbiol Infect* 14:398-405.
- Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. *Clin Infect Dis* 1996 ;22 :315-321
- Varma, A., and K. J. Kwon-Chung. Heteroresistance of *Cryptococcus gattii* to fluconazole. *Antimicrob. Agents Chemother.* 2010; 54:2303-2311.
- Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. *Am J Transplant* 2002; 2:575-580.
- Vidal JE, Penalva de Oliveira AC, Fink MC, Pannuti CS, Trujillo JR. Aids related progressive multifocal leukoencephalopathy :a retrospective study in a referral center in São Paulo, Brazil. *Rev Inst Med Trop Sao Paulo* 2008;50:209-12
- Zaragoza O, Mesa-Arango AC, Gómez-López A, Bernal-Martínez L, Rodríguez-Tudela JL, Cuenca-Estrella M. A process analysis of variables for standardization of antifungal susceptibility testing of non-fermentative yeasts. *Antimicrob. Agents Chemother.* 20101 doi:10.1128/AAC.01631-10
- Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. *PLoS ONE* 2009; 4:e5575.



Meningitis

Edited by Prof. George Wireko-Brobby

ISBN 978-953-51-0383-7

Hard cover, 232 pages

Publisher InTech

Published online 30, March, 2012

Published in print edition March, 2012

Meningitis is a medical emergency requiring a rapid diagnosis and an immediate transfer to an institution supplied with appropriate antibiotic and supportive measures. This book aims to provide general practitioners, paediatricians, and specialist physicians with an essential text written in an accessible language, and also to highlight the differences in pathogenesis and causative agents of meningitis in the developed and the developing world.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Marcia S. C. Melhem and Mara Cristina S. M. Pappalardo (2012). An Overview on Cryptococcal Meningitis, Meningitis, Prof. George Wireko-Brobby (Ed.), ISBN: 978-953-51-0383-7, InTech, Available from: <http://www.intechopen.com/books/meningitis/an-overview-on-cryptococcal-meningitis>

INTeCH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen